Literature DB >> 2556719

Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker.

J J Feigenbaum1, F Bergmann, S A Richmond, R Mechoulam, V Nadler, Y Kloog, M Sokolovsky.   

Abstract

Binding studies using the enantiomers of the synthetic cannabinoid 7-hydroxy-delta 6-tetrahydrocannabinol 1,1-dimethylheptyl homolog in preparations of rat brain cortical membranes reveal that the (+)-(3S,4S) enantiomer HU-211 blocks N-methyl-D-aspartate (NMDA) receptors in a stereospecific manner and that the interaction occurs at binding sites distinct from those of other noncompetitive NMDA antagonists or of glutamate and glycine. Moreover, HU-211 induces stereotype and locomotor hyperactivity in mice and tachycardia in rat, effects typically caused by NMDA receptor antagonists. HU-211 is also a potent blocker of NMDA-induced tremor, seizures, and lethality in mice. This compound may therefore prove useful as a nonpsychoactive drug that protects against NMDA-receptor-mediated neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556719      PMCID: PMC298542          DOI: 10.1073/pnas.86.23.9584

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  A comparison of PCP-like compounds for NMDA antagonism in two in vivo models.

Authors:  D A Bennett; P S Bernard; C L Amrick
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

Review 2.  Glutamate and the pathophysiology of hypoxic--ischemic brain damage.

Authors:  S M Rothman; J W Olney
Journal:  Ann Neurol       Date:  1986-02       Impact factor: 10.422

Review 3.  Glutamate neurotoxicity and diseases of the nervous system.

Authors:  D W Choi
Journal:  Neuron       Date:  1988-10       Impact factor: 17.173

4.  Radioligand binding to central phencyclidine recognition sites is dependent on excitatory amino acid receptor agonists.

Authors:  P Loo; A Braunwalder; J Lehmann; M Williams
Journal:  Eur J Pharmacol       Date:  1986-04-29       Impact factor: 4.432

5.  Glycine potentiates N-methyl-D-aspartate-induced [3H]TCP binding to rat cortical membranes.

Authors:  L D Snell; R S Morter; K M Johnson
Journal:  Neurosci Lett       Date:  1987-12-29       Impact factor: 3.046

6.  Ketamine and phencyclidine cause a voltage-dependent block of responses to L-aspartic acid.

Authors:  C R Honey; Z Miljkovic; J F MacDonald
Journal:  Neurosci Lett       Date:  1985-10-24       Impact factor: 3.046

7.  Cardiovascular and plasma prolactin responses to stereoisomers of phencyclidine.

Authors:  M A Bayorh; D Lozovsky; K C Rice; T R Burke; I J Kopin
Journal:  Pharmacol Biochem Behav       Date:  1983-08       Impact factor: 3.533

8.  Phencyclidine-induced stereotype in rats: effects of methadone, apomorphine, and naloxone.

Authors:  K Verebey; M J Kogan; S J Mulè
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate.

Authors:  N A Anis; S C Berry; N R Burton; D Lodge
Journal:  Br J Pharmacol       Date:  1983-06       Impact factor: 8.739

10.  Glycine potentiates the NMDA response in cultured mouse brain neurons.

Authors:  J W Johnson; P Ascher
Journal:  Nature       Date:  1987 Feb 5-11       Impact factor: 49.962

View more
  25 in total

Review 1.  Depersonalisation disorder: a contemporary overview.

Authors:  Daphne Simeon
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Derivatives of dexanabinol. II. Salts of amino acid esters containing tertiary and quaternary heterocyclic nitrogen with increased water-solubility.

Authors:  E Pop; F Soti; M E Brewster; Y Barenholz; V Korablyov; R Mechoulam; V Nadler; A Biegon
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

Review 3.  Multifunctional drugs for head injury.

Authors:  Robert Vink; Alan J Nimmo
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

4.  Slim evidence for cannabinoids for epilepsy.

Authors:  John W Miller
Journal:  Epilepsy Curr       Date:  2013-03       Impact factor: 7.500

Review 5.  Recent advances in epilepsy.

Authors:  Mark Manford
Journal:  J Neurol       Date:  2017-01-24       Impact factor: 4.849

Review 6.  [Therapeutic use of cannabinoids in neurology].

Authors:  P Schwenkreis; M Tegenthoff
Journal:  Schmerz       Date:  2003-10       Impact factor: 1.107

Review 7.  The therapeutic potential of cannabinoids for movement disorders.

Authors:  Benzi Kluger; Piera Triolo; Wallace Jones; Joseph Jankovic
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

Review 8.  Pharmacology of traumatic brain injury: where is the "golden bullet"?

Authors:  Kathryn Beauchamp; Haitham Mutlak; Wade R Smith; Esther Shohami; Philip F Stahel
Journal:  Mol Med       Date:  2008-08-18       Impact factor: 6.354

9.  The protective effect of dexanabinol (HU-211) on nitric oxide and cysteine protease-mediated neuronal death in focal cerebral ischemia.

Authors:  Ramazan Durmaz; Hilmi Ozden; Güngör Kanbak; Erinç Aral; Okan Can Arslan; Kazim Kartkaya; Kubilay Uzuner
Journal:  Neurochem Res       Date:  2008-04-11       Impact factor: 3.996

Review 10.  Cannabinoids for epilepsy.

Authors:  David Gloss; Barbara Vickrey
Journal:  Cochrane Database Syst Rev       Date:  2014-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.